Zeprumetostat clinical trials
Also written SHR2554.
How each study uses zeprumetostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zeprumetostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
39 studies that test it; most in 2026 (14)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 4 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 6 |
| 2025 | 5 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 23
Jiangsu HengRui Medicine Co., Ltd. (15) · Fudan University (4) · Institute of Hematology & Blood Diseases Hospital, China (4) · Ruijin Hospital (3) · Sun Yat-sen University (2) · Chinese PLA General Hospital (2) · Treeline Biosciences, Inc. (1) · Peking University First Hospital (1)
Often tested with
Tested in the same studies.
SHR-1701 (6) · Tucidinostat (3) · Apatinib (2) · Azacitidine (2) · Golidocitinib (2) · Linperlisib (2) · Camrelizumab (2) · Selinexor (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test zeprumetostat.
- Nov 2026A Study of TLN-254 in Participants With Relapsed or Refractory T-cell LymphomaPhase 1 · Treeline Biosciences, Inc.
- Feb 2027Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell LymphomaPhase 2 · Fudan University
- Apr 2027A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular LymphomaPhase 2 · Jiangsu HengRui Medicine Co., Ltd.
- Jul 2027PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric CancerPhase 2 · The First Affiliated Hospital of Zhengzhou University
- Sep 2027SHR2554 Combined With Endocrine Therapy in Advanced Breast CancerPhase 2 · Henan Cancer Hospital
Studies
Open first, then newest update. How each study uses zeprumetostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 39
- A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte LeukemiaRecruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT07692529Written as zeprumetostat
- SHR2554 Combined With Endocrine Therapy in Advanced Breast CancerRecruitingPhase 2Henan Cancer HospitalNCT07125950Written as SHR2554
- Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJCNot yet recruitingPhase 2Fudan UniversityNCT07874425Written as zeprumetostat
- A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaNot yet recruitingPhase 2Peking University First HospitalNCT07854639Written as Zeprumetostat Tablets
- PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric CancerRecruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07294664Written as SHR2554
- Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCLNot yet recruitingPhase 1/2Tianjin Medical University Cancer Institute and HospitalNCT07724782Written as Zeprumetostat( an EZH2 inhibitor) + X
- SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)Not yet recruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07725705Written as SHR2554 combined with Liposomal Mitoxantrone
- Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07717242Written as Zeprumetostat
- New Genotype-guided Treatment in Newly Diagnosed PTCLNot yet recruitingPhase 1/2Ruijin HospitalNCT07706959Written as Zeprumetostat plus chidamide with CHOP
- Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell LymphomaRecruitingPhase 1/2Rong TaoNCT07502768Written as Zeprumetostat
- Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular LymphomaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07555470Written as Zeprumetostat
- Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell LymphomaNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07615283Written as Adebrelimab & SHR2554
- Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCLNot yet recruitingPhase 1/2Ruijin HospitalNCT07493330Written as Zeprumetostat+Decitabine
- Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell LymphomaRecruitingPhase 2Fudan UniversityNCT06519526Written as SHR-2554
- A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate CancerRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07230106Written as SHR2554 Tablet
- Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCLRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07372352Written as Zeprumetostat
- SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell LymphomaNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07347288Written as SHR2554 Tablets
- EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell LymphomasNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07339527Written as Zeprumetostat
- SHR2554 Clinical Study of Chidamide in the Treatment of T-cell LymphomaRecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT06122389Written as SHR2554; Chidamide analog tablets
- Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer SubjectsRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07175220Written as SHR2554; SHR-A2102
See all 39 studies that test zeprumetostat →
Given beside what is tested · 2 — zeprumetostat is usual care or a partner of the new treatment
- A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate CancerRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT06568094Written as SHR2554 tablets
- TLN-121 in Relapsed or Refractory Non-Hodgkin LymphomasRecruitingPhase 1Treeline Biosciences, Inc.NCT07082803Written as zeprumetostat (TLN-254)
As the comparator · 1 — what is tested is compared with zeprumetostat
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Codes
What other systems call zeprumetostat · ClinicalTrials.gg INT018479
- UNII (FDA) XLJ9D8HE8YZEPRUMETOSTATOne source FDA
- NCI Thesaurus C158742ZeprumetostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | XLJ9D8HE8Y | ZEPRUMETOSTAT | One source FDA |
| NCI Thesaurus | C158742 | Zeprumetostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.